ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.160
-0.060 (-2.70%)
At close: Dec 16, 2025, 4:00 PM EST
2.170
+0.010 (0.46%)
After-hours: Dec 16, 2025, 6:21 PM EST
ImmunityBio Revenue
ImmunityBio had revenue of $32.06M in the quarter ending September 30, 2025, with 425.07% growth. This brings the company's revenue in the last twelve months to $82.56M, up 1,025.95% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$82.56M
Revenue Growth
+1,025.95%
P/S Ratio
23.01
Revenue / Employee
$121,404
Employees
680
Market Cap
2.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IBRX News
- 9 hours ago - ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Business Wire
- 4 days ago - ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy - Benzinga
- 4 days ago - ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - Business Wire
- 13 days ago - A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs - Seeking Alpha
- 27 days ago - A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - The Motley Fool
- 27 days ago - ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech - Seeking Alpha
- 4 weeks ago - New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations - Business Wire
- 5 weeks ago - Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 - Business Wire